Carol Gallagher joined NEA as a Partner in October, 2014. She is primarily focused on biopharma investments. Carol is a proven entrepreneur, operator and more recently investor with nearly 30 years of experience in commercial, drug development and business development roles. Prior to joining NEA she was a Venture Partner with Frazier Healthcare and she served as an independent director on multiple Boards including Aragon Pharmaceuticals, Atara Bio, AnaptysBio, Seragon Phramaceuticals, eFFECTOR, and Millendo.
From 2008-2011, Dr. Gallagher was the president and CEO of Calistoga Pharmaceuticals that developed the first-in-class cancer therapeutic, CAL-101, now known as ZYDELIG. Calistoga Pharmaceuticals was acquired by Gilead Sciences in 2011.
She currently serves as the Lead Independent Director of AtaraBio, Chairman of Millendo and as a Director at Metacrine and Pionyr Immunotherapeutics.